Research.Patient.info
Advanced Urothelial Carcinoma research hub
2 indexed studies · 2 currently recruiting
- recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04C
This study tests a new combination of targeted drugs for adults with advanced bladder or urinary tract cancer. Researchers are checking whether a new drug called MK-2870 works safely when given with enfortumab vedotin, with or without an immunotherapy drug, to help shrink tumours and stop cancer growing.
France · Spain · Denmark - recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma
This study is looking at new treatments for advanced bladder cancer that has spread. It combines pembrolizumab and enfortumab vedotin, sometimes with other new medicines, to see if they are safe and work well as a first treatment.
Netherlands · Spain · Italy